Trials / Unknown
UnknownNCT05117658
Study of HA121-28 in Patients With Non-Small Cell Lung Cancer
A Single-Arm, Multi-Centre, Open-Label Phase II Study of HA121-28 in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 83 (estimated)
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, open-label, single-arm phase II study to evaluate efficacy and safety of HA121-28 tablets in patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HA121-28 tablet | HA121-28 tablet, 450 mg, po, QD×21 days, every 4 weeks (28 days) |
Timeline
- Start date
- 2022-02-18
- Primary completion
- 2023-10-01
- Completion
- 2023-10-01
- First posted
- 2021-11-11
- Last updated
- 2022-08-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05117658. Inclusion in this directory is not an endorsement.